title: The role of fluorodeoxyglucose positron emission tomography-computerized tomography in resolving therapeutic dilemmas in pediatric Hodgkin lymphoma.
abstract: BACKGROUND
  Hodgkin lymphoma (HL) is a highly curable lymphoma with cure rates of over 80% and even higher with limited stage disease. Computerized tomography (CT) scan is currently the recommended modality in staging and assessment of response to therapy in patients with HL. However, CT has its limitations. This study describes our experience with patients of HL where fluorodeoxyglucose positron emission tomography (FDG-PET)-CT scan helped decide further management, after completion of chemotherapy.
  
  
  METHODS
  This is a retrospective review of the records of children diagnosed with HL at our center. Patients with post-treatment CT scan showing evidence of residual disease, who underwent FDG-PET-CT for deciding further management, were included in the study.
  
  
  RESULTS
  Thirty one patients were diagnosed with HL during this period. Nine patients were eligible and underwent PET-CT. In 8 out of 9 patients, PET-CT showed no scan evidence of active disease. In one patient, FDG-PET-CT carried out after completion of chemotherapy showed evidence of active disease and was given radiotherapy.
  
  
  CONCLUSIONS
  FDG-PET-CT is a promising modality in deciding further management when there is discordance between the post-treatment CT scan and clinical condition of the patient with HL thus avoiding unnecessary chemotherapy/radiotherapy.
authors.affiliation: Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
authors.forename: Rachna
authors.initials: R
authors.lastname: Seth
authors.forename: Kriti
authors.initials: K
authors.lastname: Puri
authors.forename: Prashant
authors.initials: P
authors.lastname: Singh
authors.forename: Panneer
authors.initials: P
authors.lastname: Selvam
authors.forename: Rakesh
authors.initials: R
authors.lastname: Kumar
keywords: Children; hodgkin lymphoma; positron emission tomography-computerized tomography
references.citation: Cancer. 2001 Jan 15;91(2):302-10
references.pmid: 11180075
references.citation: Br J Haematol. 2001 Nov;115(2):272-8
references.pmid: 11703321
references.citation: Ann Oncol. 2006 Aug;17(8):1296-300
references.pmid: 16766583
references.citation: Haematologica. 2010 Jul;95(7):1046-8
references.pmid: 20595100
references.citation: Oncol Rep. 2001 Nov-Dec;8(6):1393-9
references.pmid: 11605073
references.citation: Blood. 2005 Aug 15;106(4):1473-8
references.pmid: 15870180
references.citation: Mol Pathol. 2000 Oct;53(5):262-9
references.pmid: 11091850
references.citation: Pediatr Blood Cancer. 2007 Apr;48(4):399-402
references.pmid: 16514616
references.citation: Nat Clin Pract Oncol. 2008 Sep;5(9):543-56
references.pmid: 18679394
references.citation: J Clin Oncol. 2007 Feb 10;25(5):579-86
references.pmid: 17242396
references.citation: J Pediatr Hematol Oncol. 2006 Nov;28(11):711-4
references.pmid: 17114956
references.citation: Mayo Clin Proc. 2012 Jun;87(6):571-80
references.pmid: 22677077
references.citation: Cancer. 2010 Aug 15;116(16):3835-42
references.pmid: 20564135
references.citation: N Engl J Med. 2007 Nov 8;357(19):1916-27
references.pmid: 17989384
references.citation: Hematology Am Soc Hematol Educ Program. 2006;:259-65, 510-1
references.pmid: 17124070
references.citation: Ann Oncol. 2001 Jan;12(1):29-37
references.pmid: 11249046
references.citation: Haematologica. 2006 Apr;91(4):522-9
references.pmid: 16585017
references.citation: J Clin Oncol. 2009 Sep 10;27(26):4385-91
references.pmid: 19667276
references.citation: Haematologica. 2006 Apr;91(4):475-81
references.pmid: 16585014
references.citation: Blood. 2006 Jan 1;107(1):52-9
references.pmid: 16150944
references.citation: J Nucl Med. 2008 Jan;49(1):13-21
references.pmid: 18077527
references.citation: Blood. 2007 Nov 15;110(10):3507-16
references.pmid: 17709603